Get the Stockscreener App
44.29
1.40%
-0.63
After Hours:
44.29
Sanofi Adr stock is traded at $44.29, with a volume of 2.76M.
It is down -1.40% in the last 24 hours and down -5.57% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$44.92
Open:
$44.84
24h Volume:
2.76M
Relative Volume:
0.84
Market Cap:
$105.85B
Revenue:
$49.41B
Net Income/Loss:
$5.59B
P/E Ratio:
18.55
EPS:
2.3875
Net Cash Flow:
$8.32B
1W Performance:
+3.75%
1M Performance:
-5.57%
6M Performance:
-10.76%
1Y Performance:
-15.65%
1-Day Range:
$44.23
$45.12
1-Week Range:
$43.02
$45.12
52-Week Range:
$42.33
$53.03
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
44.29 | 107.36B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Sanofi S.A. stock (FR0000127771): EU green light for multiple myeloma drug Sarclisa draws investor f - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Vaccine unit and new drug launches keep investors alert - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Q1 beat and pipeline focus keep investors watching - AD HOC NEWS
Sanofi stock (FR0000120578): Pipeline updates keep investors watching - AD HOC NEWS
Sanofi stock (FR0000120578): trial data and EU approval updates - AD HOC NEWS
1 Dirt Cheap Growth Stock to Buy Right Now - The Motley Fool
Sanofi stock (FR0000120578): Dupixent data and AI investment keep focus on growth - AD HOC NEWS
Sanofi stock (FR0000120578): FDA, dividend and Dupixent keep investors focused - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Q1 figures, GLP-1 hopes and focus on pipeline value - AD HOC NEWS
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi S.A. stock (FR0000120578): Q1 2026 results reviewed - AD HOC NEWS
Sanofi S.A. stock (FR0000120578): Global pharma leader's business and market position - AD HOC NEWS
Sanofi S.A. stock (FR0000127771): Recent earnings and pipeline updates - AD HOC NEWS
Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals - ChartMill
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 - ChartMill
European ADRs Open The Week Lower In US Trading - Finimize
Communiqué de presse : Assemblée Générale Annuelle du 29 avril 2026 - GlobeNewswire Inc.
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat - Sahm
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision - Sahm
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises - Investing.com
Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises By Investing.com - Investing.com Canada
Sanofi S.A. stock (FR0000127771): Is its biopharma pivot strong enough to unlock new upside? - AD HOC NEWS
Sanofi ADS (SNY) In-Depth Look | Sanofi ADS posts 4.6% EPS beat on pharma revenueADR - Newser
Sanofi S.A. stock (FR0000127771): Is its immunology pipeline strong enough to unlock new upside? - AD HOC NEWS
SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK
Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
2.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):